The purpose of this study is to determine how effective the combination of these medications is at eliminating cancer cells before surgery. The treatment is given in two phases – before surgery (called neoadjuvant treatment) and after surgery (called adjuvant treatment). Before surgery, patients receive both medications. After surgery, all patients receive zimberelimab, and some patients may also continue receiving sacituzumab govitecan.

During the study, patients will receive regular medical examinations and various tests to monitor their health and how well the treatment is working. The treatment period may last up to 54 weeks. Zimberelimab is given at doses up to 360 milligrams, while sacituzumab govitecan is given based on the patient’s body weight, up to 10 milligrams per kilogram of body weight.

The main goal is to see how well the first set of medicines controls the cancer and to assess how the second‑line medicines affect breathing problems caused by the lung disease. Participants receive a series of intravenous infusions over several weeks, followed by regular check‑ups that include blood tests and imaging. Imaging is performed with a CT scan, which is a special X‑ray that creates detailed pictures of the lungs and chest.

After the initial treatment period, patients are monitored for up to six months to record any worsening of breathing that might require stopping the medication, as well as overall health outcomes such as how long the disease stays stable and overall survival. All side effects are recorded and graded according to standard cancer‑treatment safety guidelines. The study follows a set schedule of clinic visits, drug administration, and imaging assessments.

Participants in the study will receive these medications through intravenous infusion, which means the medicine is delivered directly into a vein. The research is divided into different stages to determine the safest and most effective dose of the medicine. During the first part, the focus is on how well the body tolerates the combination of drugs. The subsequent parts aim to see how well the treatments work to reduce the size or growth of the tumors.

The treatments involve medications administered through an Intravenous line, which is a method of delivering medicine directly into a vein. One group receives the study drug PF-08634404 along with a combination of chemotherapy drugs, which may include Paclitaxel, Carboplatin, or Pemetrexed. Another group receives Pembrolizumab combined with these chemotherapy drugs. Some participants may also receive Paclitaxel Albumin-Bound or a Placebo involving Sodium Chloride. During the study, participants will be monitored to see how they respond to the medicines and to track their Overall Survival and Progression-Free Survival, which refers to the length of time during and after treatment that a person lives with the disease without it getting worse.

The study is divided into two parts to determine the best way to use these medicines. In the first part, different amounts of the drugs are given to find the safest and most effective dose. The second part focuses on finding the optimal dose and observing how well the combination works for different types of lung cancer. Throughout the process, the safety and how the body processes the drugs are closely monitored.

The study is divided into different parts. The first part will test different dose levels of the investigational medications to find the most suitable dose for further testing. During this phase, doctors will carefully monitor participants for any side effects. The following parts of the study will test the chosen dose in larger groups of people with advanced non-small cell lung cancer to better understand how well the treatment works and how safe it is. Throughout the study, participants will receive the medications through infusion into a vein. Doctors will regularly check how the cancer responds to treatment using imaging scans and other assessments.

During the study, participants will need to provide a tissue sample from their tumor, either from a previously stored sample or from a new biopsy if needed. The study will track various aspects of participant health and treatment response, including any side effects that occur, whether the cancer shrinks or stops growing, and how long any positive effects last. Blood samples will be collected at different times to measure the levels of the investigational medications in the body and to check whether the immune system develops a response to these medications.

The purpose of this study is to compare how well MK-2870 combined with pembrolizumab works compared to pembrolizumab alone in preventing the cancer from coming back after surgery. Before being assigned to one of these treatment groups, participants will first receive pembrolizumab along with platinum-based chemotherapy before surgery, which is called neoadjuvant treatment. After surgery, if cancer cells are still found in the removed tissue, meaning a complete response was not achieved, participants will then be randomly assigned to receive either MK-2870 plus pembrolizumab or pembrolizumab alone as adjuvant treatment, which means treatment given after surgery to reduce the risk of cancer returning.

During the study, participants will have regular check-ups that include imaging scans such as computed tomography or magnetic resonance imaging to monitor for any signs of cancer returning. The study will measure how long participants remain free of disease, how long they survive overall, and whether the cancer spreads to distant parts of the body. Researchers will also assess quality of life and monitor for any side effects throughout the treatment period. The treatment period can last up to several months, and participants will continue to be followed for a number of years to track long-term outcomes.

For breast cancer patients, the study involves receiving Atorvastatin alongside standard immunotherapy and chemotherapy before surgery. For lung cancer patients, Atorvastatin will be given with first-line immunotherapy. The researchers will collect tumor samples and blood samples at different timepoints to analyze how the combination treatment affects the immune response in the tumor and the presence of cancer DNA in the blood.

The trial will monitor both how well the treatment works against the cancer and any side effects that may occur. Various advanced laboratory techniques will be used to understand how Atorvastatin affects the immune system’s response to cancer and to identify markers that might predict which patients will benefit most from this combination approach.

The purpose of the study is to evaluate the safety and effectiveness of BNT327 when used with chemotherapy. The trial is divided into two phases: Phase II and Phase III. In Phase II, the focus is on assessing how safe and tolerable BNT327 is at different dose levels when combined with chemotherapy. In Phase III, the study will compare the effectiveness of BNT327 combined with chemotherapy to the combination of pembrolizumab and chemotherapy. The study will also look at how these treatments affect the progression of the disease and overall survival of participants.

Participants in the study will receive treatment over a period of time, with regular follow-up visits to monitor their health and the effects of the treatment. The study aims to provide valuable information on the potential benefits and risks of using BNT327 in treating non-small cell lung cancer, which could lead to new treatment options for patients in the future.

The purpose of this study is to evaluate the safety and effectiveness of the combination of ABBV-400 and Budigalimab in patients with advanced or metastatic non-squamous NSCLC. Participants in the study will receive these medications through an intravenous infusion, which means the drugs are given directly into the bloodstream through a vein. The study will monitor participants for any side effects and changes in their cancer to determine the best dose for future studies.

Throughout the study, participants will be closely observed to assess how their cancer responds to the treatment. The study aims to find out if this combination can help control the disease and improve the quality of life for patients with this type of lung cancer. The trial will continue until the researchers gather enough information to understand the treatment’s impact on the disease.

The purpose of the study is to see if using Pembrolizumab as a maintenance therapy after patients have received a combination of chemotherapy and radiation therapy can help improve their overall survival. The study will compare two groups of patients: one group will receive Pembrolizumab for up to 24 months, while the other group will be observed without additional treatment after their initial therapy. This will help researchers understand if Pembrolizumab can provide better outcomes for patients with this type of lung cancer.

Participants in the study will first undergo chemotherapy and radiation therapy. After this initial treatment, they will either receive Pembrolizumab or be placed under observation. The study will monitor the patients over time to assess their overall survival and how long they remain free from cancer progression. The goal is to determine if Pembrolizumab can extend the lives of patients with stage III NSCLC compared to those who do not receive the maintenance therapy.

The purpose of this research is to determine how effective a combined treatment approach is for patients with this type of lung cancer. The treatment plan includes initial therapy with immunotherapy and chemotherapy, followed by either surgery or a combination of chemotherapy and radiation therapy. After these treatments, patients receive additional immunotherapy for up to 12 months.

During the study, patients will receive medications through infusion, which means the drugs are given directly into a vein. Doctors will monitor how well the treatment works and track any side effects that may occur. The study will measure how long patients live without their cancer getting worse or returning after treatment begins.

The purpose of the study is to compare the effects of the combination of CC-486 and pembrolizumab against pembrolizumab with a placebo in patients with NSCLC. Participants in the study will be randomly assigned to receive either the combination treatment or pembrolizumab with a placebo. The study will monitor the participants over a period to assess how well the treatments work and to check for any side effects. The trial will help researchers understand if the combination of CC-486 and pembrolizumab can improve outcomes for patients with this type of lung cancer.

Throughout the study, participants will receive regular check-ups and monitoring to ensure their safety and to track the progress of their treatment. The study is expected to continue until 2025, providing valuable information on the potential benefits and risks of using CC-486 in combination with pembrolizumab for treating advanced NSCLC. This research could lead to new treatment options for patients with this challenging form of lung cancer.

The purpose of the study is to evaluate the safety and effectiveness of combining Durvalumab with two different types of radiation therapy. One type is the conventional method, and the other is an optimized method called hypofractionated radiotherapy, which involves giving larger doses of radiation over a shorter period. The study aims to see how well these treatments work together in improving the response rates in patients with this type of lung cancer.

Participants in the study will receive either the conventional or the hypofractionated radiation therapy along with Durvalumab. The study will monitor the safety of these treatments and how well they are tolerated by the patients. It will also look at how the cancer responds to the treatment over time. The study is expected to last for a period of up to 12 months, during which patients will have regular hospital visits for treatment and follow-up examinations.

The purpose of the study is to evaluate how well this combination of treatments works in preventing the cancer from getting worse over a period of two years. Participants in the study will receive either the full combination of treatments, including durvalumab, or a similar treatment plan without durvalumab. The study will last for about 32 weeks, during which participants will undergo various treatments and follow-up visits to monitor their health and the progress of the cancer.

Throughout the study, researchers will be looking at several outcomes, including how long participants live without the cancer progressing, overall survival rates, and any side effects related to the treatments. The study will also assess the quality of life of participants during and after the treatment. This information will help determine the potential benefits and risks of using durvalumab in combination with other therapies for treating stage III non-small cell lung cancer.

Participants in the study will receive treatments through an intravenous infusion, which means the medication is given directly into a vein. The medications used in the study include cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, which are all types of chemotherapy drugs. These drugs work by targeting and killing cancer cells. The study will also use durvalumab, an immunotherapy drug that helps the immune system recognize and attack cancer cells.

The study will take place over a period of time, with participants receiving treatment for up to 16 weeks. The goal is to determine if adding durvalumab after the initial treatment can help prevent the cancer from returning. Participants will be monitored throughout the study to assess their response to the treatment and any side effects they may experience. The study is designed to provide valuable information on improving treatment outcomes for patients with early-stage NSCLC.

The purpose of the study is to evaluate the effectiveness and safety of these treatments when given before and after surgery. The study will follow a course where patients receive the treatments before surgery to shrink the tumor, known as neoadjuvant treatment, and then continue with additional treatments after surgery, known as adjuvant treatment. The study aims to see how well these treatments work in reducing the cancer and how safe they are for patients.

Participants in the study will receive either the active medications or a placebo. The study will monitor the response of the cancer to the treatments, as well as any side effects experienced by the participants. The goal is to gather information that could help improve treatment options for patients with early-stage NSCLC that can be surgically removed.

The study is divided into different parts. Initially, all participants will receive the treatment to see how well it is tolerated. After this, participants will be randomly assigned to receive either the combination of GB1211 and atezolizumab or atezolizumab with a placebo. This part of the study is conducted without participants knowing which treatment they are receiving. The study will also include an extension phase to observe the long-term effects of the treatment.

Participants will take part in regular check-ups and assessments to monitor their health and the progress of their cancer. The study aims to provide valuable information on whether the combination of GB1211 and atezolizumab can improve outcomes for patients with NSCLC. The study is expected to continue until 2025, allowing researchers to gather comprehensive data on the treatment’s safety and effectiveness over time.

Participants in the study will receive either Ensartinib or Crizotinib. The study will monitor the progress of the disease and any side effects experienced by the participants. The trial will last for a period of time, during which participants will have regular check-ups and assessments to track their health and the cancer’s response to the treatment. The study aims to determine which medication is more effective in controlling the cancer and improving the quality of life for patients.

This trial is important for understanding the best treatment options for patients with ALK-positive NSCLC. By comparing these two medications, researchers hope to find the most effective way to manage this type of lung cancer and provide better outcomes for patients. Participants will be closely monitored throughout the study to ensure their safety and to gather valuable information about the treatments being tested.

The study is divided into several parts. In some parts, patients will receive tisotumab vedotin alone, while in others, it will be given alongside pembrolizumab or both pembrolizumab and a platinum agent like cisplatin or carboplatin. These medications are administered through an intravenous infusion, which means they are given directly into the bloodstream through a vein. The study will observe the effects of these treatments over time to understand their impact on the cancer and any side effects that may occur.

The purpose of this study is to assess the antitumor activity of tisotumab vedotin and its combinations in treating these advanced cancers. The study will monitor how the tumors respond to the treatment, how long it takes for a response to occur, and the overall survival of the patients. This information will help determine the effectiveness and safety of the treatment options being tested.

The purpose of the study is to determine if the combination of Niraparib and Pembrolizumab can help patients live longer without the disease getting worse, and to see if it can improve overall survival compared to the placebo. Participants in the study will have already received a first-line treatment with platinum-based chemotherapy and Pembrolizumab, and their disease should have either remained stable or shown improvement. The study will involve regular monitoring and assessments to track the progress of the disease and the effects of the treatment.

Throughout the study, participants will receive either the combination of Niraparib and Pembrolizumab or a placebo with Pembrolizumab. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are unbiased. The study will continue for a set period, during which participants will be closely monitored for any changes in their condition and any side effects they may experience. The ultimate goal is to find a more effective maintenance therapy for patients with advanced or metastatic NSCLC.

The main purpose of this research is to evaluate how well the combination of these medications works in treating this type of lung cancer. The study will track how patients respond to treatment over time, including how the cancer responds and what side effects may occur. Some patients will receive brigatinib alone, while others will receive brigatinib together with carboplatin and pemetrexed.

During the study, patients will receive regular medical check-ups and undergo various tests to monitor their health and how well the treatment is working. The treatment period may last up to 60 months, with regular assessments of the cancer’s response to treatment. The medications will be given in specific doses, with brigatinib taken daily as tablets, while carboplatin and pemetrexed will be given through an intravenous line at scheduled intervals.

Participants in the study will be randomly assigned to one of two groups. One group will receive Ociperlimab in combination with Tislelizumab, while the other group will receive Pembrolizumab followed by a placebo. The treatments are given as infusions, which means they are administered directly into the bloodstream through a vein. The study will monitor the participants over a period of time to assess the effectiveness of the treatments in improving survival rates.

The trial aims to provide valuable information on how these treatments can help patients with non-small cell lung cancer. By comparing the different treatment options, researchers hope to find the most effective approach for managing this type of cancer. The study will also look at the quality of life of participants and any side effects they may experience during the trial.

The main goal of the study is to assess the safety and how well patients tolerate ATL001 as a treatment. Participants in the study will receive the treatment through an infusion, which means the medication is given directly into the bloodstream. The study will monitor patients over time to see how their cancer responds to the treatment and to check for any side effects. The study will also compare the effects of the treatment with those of a placebo.

Throughout the study, patients will have regular check-ups to track their health and the progress of their cancer. The study will measure changes in tumor size and overall health outcomes, such as how long patients live without their cancer getting worse. This research aims to provide new insights into treating non-small cell lung cancer and potentially offer new options for patients with this type of cancer.

Participants in the study will take Lorlatinib orally, which means by mouth, for a period of up to 72 weeks. The study will monitor the participants’ response to the treatment, including any changes in their cancer and overall health. The study aims to see if Lorlatinib can help control the cancer and improve the patients’ quality of life. Throughout the study, participants will have regular check-ups and tests to track their progress and any side effects they might experience.

The study will also look at how long participants live without their cancer getting worse, known as progression-free survival, and overall survival, which is the time from starting the treatment until death from any cause. Additionally, the study will assess the impact of Lorlatinib on brain metastases, which are cancer cells that have spread to the brain. Participants will be closely monitored to ensure their safety and to gather information on how well the treatment works in different molecular subgroups of patients with this type of lung cancer.

The purpose of the study is to explore the possibility of performing surgery after patients have received high-dose chemotherapy and radiation therapy, which is a combination treatment often referred to as chemoradiotherapy. After surgery, the study will also look at whether patients can continue with Durvalumab as a follow-up treatment, known as consolidation therapy. This approach aims to see if adding surgery and Durvalumab can be a feasible treatment plan for patients with Stage III NSCLC.

Participants in the study will first undergo chemoradiotherapy. If surgery is deemed possible, it will be performed within 12 weeks after completing the chemoradiotherapy. Following surgery, patients will receive Durvalumab to help consolidate the treatment. The study will monitor the ability to perform surgery and the continuation of Durvalumab treatment, as well as any side effects or complications that may arise during the process.

Participants in the study will receive treatment with amivantamab for four weeks. In the first stage, amivantamab will be given by itself. In the second stage, it will be combined with carboplatin and pemetrexed disodium. After the treatment, patients will undergo surgery to remove the cancer. If needed, additional treatments such as chemotherapy, radiation therapy, or medications targeting EGFR mutations may be provided after surgery.

The study aims to determine if this approach is feasible and safe for patients with early-stage or locally advanced non-small-cell lung cancer that can be surgically removed. The study will also look at how the cancer responds to the treatment and how it affects the patient’s health and recovery after surgery.

Participants in the study will take INCB099280 in the form of a film-coated tablet. The study will test different doses of the medication, specifically 400 mg, 600 mg, and 800 mg, taken twice a day. The treatment period can last up to 24 weeks. During the study, participants will be monitored for any side effects and changes in their condition. Some participants may receive a placebo, which is a tablet that looks like the treatment but does not contain the active medication.

The study aims to gather information on how the treatment affects the tumors, including whether it can shrink them or stop them from growing. It will also look at how long any positive effects last and how the treatment impacts the overall health and survival of the participants. The results will help determine if INCB099280 could be a useful treatment option for people with these types of cancer in the future.

The purpose of this study is to see how well these treatments work in preventing the cancer from getting worse. Participants in the trial will be randomly assigned to receive either Repotrectinib or Crizotinib. The study will monitor the participants over time to assess the effectiveness of the treatments in controlling the cancer. This will involve regular check-ups and assessments by medical professionals to track the progress of the disease and any side effects from the medications.

Throughout the study, the main focus will be on how long the participants can live without their cancer progressing, which is known as progression-free survival. Other aspects being studied include overall survival, how well the cancer responds to the treatment, and the duration of this response. The trial will also look at the time it takes for the treatment to start working and any potential side effects. The study aims to provide valuable information that could help improve treatment options for people with this type of lung cancer in the future.

The purpose of the study is to assess how well these medications work together in treating this type of lung cancer. Participants in the study will receive either a combination of Paclitaxel and Bevacizumab or a combination of Paclitaxel, Bevacizumab, and Atezolizumab. Some participants may receive a placebo instead of Atezolizumab. The study will monitor the participants over a period of time to see how their cancer responds to the treatment and to check for any side effects.

Throughout the study, participants will have regular visits to the clinic for their treatments and to undergo various tests. These tests will help the researchers understand how the cancer is responding to the treatment and to ensure the safety of the participants. The study aims to provide valuable information that could lead to better treatment options for patients with advanced non-squamous NSCLC in the future.